Welcome to our dedicated page for Advanced Micro Devices SEC filings (Ticker: AMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Advanced Micro Devices� disclosures are as multifaceted as its silicon roadmap. Whether you’re tracking wafer supply commitments for Ryzen CPUs, margins on Radeon GPUs, or integration costs from the Xilinx acquisition, AMD’s 10-K and 10-Q filings hold the details that move markets. Yet wading through hundreds of pages is time-consuming.
Stock Titan’s AI engine turns that problem into clarity. Our platform delivers AMD SEC filings explained simply, with sentence-level summaries layered atop the original documents. Need instant alerts on an AMD 8-K material events explained note, or to verify AMD Form 4 insider transactions real-time? We stream every submission from EDGAR within seconds, tag the numbers that matter, and surface red-flag language you might miss.
Investors use these insights to:
- Compare segment revenue and gross margin trends in each AMD quarterly earnings report 10-Q filing.
- See how stock-based awards shift in the latest AMD proxy statement executive compensation.
- Monitor AMD insider trading Form 4 transactions and set watchlists for key officers.
- Dive into capex guidance with our AMD earnings report filing analysis.
- Download an AMD annual report 10-K simplified for quick reference.
- Track large option exercises through AMD executive stock transactions Form 4.
- Ask natural questions like �understanding AMD SEC documents with AI� and get immediate answers.
No spreadsheets to build, no jargon to untangle—just the data, the context, and the confidence to act before the market fully digests AMD’s next disclosure.
Herc Holdings (HRI) Form 8-K � Cinelease divestiture
On 31 Jul 2025 the company closed the sale of its Cinelease studio entertainment and lighting & grip equipment-rental business to private platform Zello. Herc received $100 million in upfront cash plus undisclosed earn-out potential under a Sale and Purchase Agreement. Management will apply the net proceeds to repay borrowings under its credit facility.
No revenue, EBITDA or gain/loss figures for Cinelease are provided. The transaction monetises a non-core asset, improves liquidity and is expected to lower leverage, but removes an unquantified earnings contributor and leaves total consideration partly contingent on future performance.
Amaze Holdings, Inc. (NYSE American: AMZE), formerly Fresh Vine Wine, filed an 8-K dated 11 July 2025 to disclose a new consulting agreement and related unregistered share issuance.
- Consulting Agreement: Signed 11 July 2025 with DNA Holdings Venture Inc. (Puerto Rico) for a 12-month term, auto-renewable for another 12 months unless cancelled on 30-days notice.
- Scope of Services: Crypto strategy & token architecture, e-commerce/Web3 integration, cross-border currency solutions, credibility/visibility support and market-making for the Company’s planned Token Generation Event.
- Consideration: Company issued 100,000 common shares to the Consultant. No cash payment disclosed.
- Unregistered Securities: Shares issued under Section 4(a)(2) and/or Rule 506(b) of Regulation D, relying on the private-offering exemption.
- Reg FD: A press release announcing the agreement was furnished as Exhibit 99.1 on 15 July 2025.
- Exhibits: 10.1 (Consulting Agreement), 99.1 (Press Release), 104 (Cover Page iXBRL file).
No financial performance metrics were provided in this filing. The transaction introduces crypto-related strategic initiatives while creating modest share dilution.
Form 4 filing overview: On 06/30/2025, MAIA Biotechnology, Inc. (ticker MAIA) granted director Cristian Luput a package of stock options under the company’s 2021 Equity Incentive Plan.
- Options granted: 21,350 options to purchase common shares.
- Exercise price: $1.80 per share.
- Vesting schedule: 100% vested immediately on the grant date.
- Expiration: 06/30/2035 (10-year term).
- Post-transaction holdings: Luput now holds 21,350 derivative securities directly.
No non-derivative share transactions were reported, and the filing was made individually by the director. The grant represents routine equity compensation designed to align director incentives with shareholder value, but it modestly increases the company’s fully diluted share count.